Olanzapine for the Prophylaxis and Rescue of Chemotherapy-Induced Nausea and Vomiting (CINV): A Retrospective Study

Chemotherapy Induced Nausea and Vomiting in Gynecological Cancer Patients: "Treatment-Related" and "Patient-Related" Risk Factors A study was undertaken to define risk factors that influence the experience of nausea and vomiting after the first therapeutic infusion in 94 patients with gynecologic cancer (Abstract 0419). Data were gathered from several sources: a questionnaire that collected sociodemographic and clinical information, as well as potential risk factors; the State-Trait Anxiety Inventory, a widely used measure of anxiety in clinical trials; the Multinational Association of Supportive Care in Cancer (MASCC) Antiemesis Tool to assess whether patients receiving chemotherapy are experiencing CINV; and a questionnaire for reporting symptoms. Multiple regression analyses found that patients who were working full-time or part-time were less likely to experience acute or delayed nausea (P=.002 and P=.045, respectively) than patients who did not work during treatment. Patients who experienced nausea during previous chemotherapy treatments were more likely to experience nausea during the current treatment in the acute (P=.020) and delayed (P=.019) phases. Acute nausea was more likely in younger patients (P=.001) and in patients who habitually ingested alcohol (P=.047). Delayed nausea was more likely in patients with a heightened state of anxiety (P=.029). Treatment emetogenicity was associated with delayed vomiting (P=.029).